• Merck initiates the Phase 3 ENHANCE-3 trial of Ohtuvarye ensifentrine inhalation suspension for the prevention of COPD exacerbations

  Merck has announced the initiation of the Phase 3 ENHANCE-3 study of Ohtuvarye ensifentrine inhalation suspension, which is expected to enroll 2,136 COPD patients and will evaluate Ohtuvarye for the prevention of exacerbations. Merck acquired… [Read more . . .]

• FDA clears IND for Phase 1 trial of United Therapeutics’ treprostinil / iloprost SMI

  Following soon after United Therapeutics’ announcement that the FDA had cleared an IND for a Phase 2 trial of the company’s treprostinil SMI in patients with PH-COPD, the company has announced an IND clearance for… [Read more . . .]

• Phase 2a trial of AerTherapeutics’ nebulized fexlamose failed to meet primary or secondary endpoints

  Aer Therapeutics has announced that a Phase 2a trial of fexlamose (AER-01) inhalation solution in patients with moderate-to-severe COPD failed to meet primary or secondary endpoints and also demonstrated an increased incidence of adverse events… [Read more . . .]

• Blue Lake gets $5 million grant from the Gates Foundation for expansion of Phase 1/2a pediatric trial of intranasal vaccine against RSV

  Blue Lake Biotechnology announced that it has received a $5 million grant from the Gates Foundation to support the addition of younger children to a Phase 1/2a clinical trial of its BLB201 nasal vaccine against… [Read more . . .]

• DDL 2026 will feature the launch of a new incubator

  This year’s Drug Delivery to the Lungs (DDL) meeting will introduce a few innovations to its regular program of scientific lectures, industry and poster exhibitions, including the new DDL Incubator. DDL 2026 will take place… [Read more . . .]

• Aptar Pharma acquires Pulmotree and its Kolibri mesh nebulizer

• Aptar names Virginie Maes as incoming President of Aptar Pharma

• Nano24 announces that Phase 2b trial of its EXO-CD24 inhaled exosome in ARDS met its primary endpoint

• FDA clears United Therapeutics IND for Phase 2 SUMMIT trial of treprostinil SMI in patients with PH-COPD

• Aptar Pharma’s LuerVax intranasal vaccine delivery device gets CE mark

More news . . .